MARKET

VTVT

VTVT

VTV THERAPEUTICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.030
+0.060
+3.05%
After Hours: 2.020 -0.01 -0.49% 16:13 07/28 EDT
OPEN
1.990
PREV CLOSE
1.970
HIGH
2.040
LOW
1.970
VOLUME
216.99K
TURNOVER
--
52 WEEK HIGH
4.750
52 WEEK LOW
1.440
MARKET CAP
169.07M
P/E (TTM)
-12.7995
1D
5D
1M
3M
1Y
5Y
vTv Therapeutics (NASDAQ:VTVT) Share Prices Have Dropped 66% In The Last Five Years
Generally speaking long term investing is the way to go. But no-one is immune from buying too high. For example, after...
Simply Wall St. · 1d ago
BRIEF-Vtv Therapeutics Says From Time To Time May Offer, Sell Shares Of Class A Common Stock Of Up To $50.0 Million
reuters.com · 06/25 20:56
Where Do Hedge Funds Stand On vTv Therapeutics Inc (VTVT)?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money invest...
Insider Monkey · 06/23 01:48
Sector Update: Health Care
MT Newswires · 06/22 15:47
Why Moderna, Bio-Path Holdings And vTv Therapeutics Are Moving Today
Moderna, Inc. (NASDAQ: MRNA), Bio-Path Holdings, Inc. (NASDAQ: BPTH) and vTv Therapeutics Inc.
Benzinga · 06/22 14:45
vTv Therapeutics Shares Jump On Out-Licensing Agreement For Azeliragon In Cancer Settings
Benzinga · 06/22 14:11
Thinking about buying stock in vTv Therapeutics, Score Media and Gaming, Bio-Path Holdings, Anavex Life Sciences, or Atossa Therapeutics?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VTVT, SCR, BPTH, AVXL, and ATOS.
PR Newswire - PRF · 06/22 12:30
Tuesday’s Pre-Market: Here’s What You Need to Know Before the Market Opens
U.S. stock futures jumped on Tuesday as investors await data of the National Association of Realtors’ existing home sales for May and the non-manufacturing business data of the Federal Reserve Bank of Philadelphia. Both sets of data are scheduled to be rel...
TipRanks · 06/22 12:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VTVT. Analyze the recent business situations of VTV THERAPEUTICS through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VTVT stock price target is 6.75 with a high estimate of 7.50 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 66
Institutional Holdings: 5.00M
% Owned: 6.00%
Shares Outstanding: 83.29M
TypeInstitutionsShares
Increased
21
1.42M
New
13
1.11M
Decreased
9
37.74K
Sold Out
8
198.21K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.42%
Pharmaceuticals & Medical Research
+1.82%
Key Executives
Chairman/Executive Director
Robin Abrams
President/Chief Executive Officer
Stephen Holcombe
Chief Financial Officer/Executive Vice President
Rudy Howard
Director
Hersh Kozlov
Director
Richard Nelson
Independent Director
John Fry
Independent Director
Noel Spiegel
Independent Director
Howard Weiner
No Data
  • All
  • Financials
  • Insiders
More
About VTVT
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

Webull offers kinds of vTv Therapeutics Inc stock information, including NASDAQ:VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VTVT stock methods without spending real money on the virtual paper trading platform.